Edition:
India

Strides Pharma Science Ltd (SRID.NS)

SRID.NS on National Stock Exchange of India

381.05INR
3:57pm IST
Change (% chg)

Rs1.10 (+0.29%)
Prev Close
Rs379.95
Open
Rs382.00
Day's High
Rs384.00
Day's Low
Rs377.10
Volume
265,503
Avg. Vol
1,441,063
52-wk High
Rs551.40
52-wk Low
Rs288.00

Latest Key Developments (Source: Significant Developments)

Strides Pharma: Ranitidine Tablets Tested By USFDA Are Within Acceptable NDMA Limits
Monday, 4 Nov 2019 

Nov 4 (Reuters) - Strides Pharma Science Ltd ::RANITIDINE TABLETS 300 MG LOTS TESTED BY USFDA ARE WITHIN ACCEPTABLE NDMA LIMITS.  Full Article

Strides Pharma Receives USFDA Approval For Solifenacin Succinate Tablets
Friday, 27 Sep 2019 

Sept 27 (Reuters) - Strides Pharma Science Ltd ::RECEIVES USFDA APPROVAL FOR SOLIFENACIN SUCCINATE TABLETS.  Full Article

Sihuan Pharma Holdings Group Says Unit, Strides Pharma Global Establish JV
Tuesday, 30 Jul 2019 

July 30 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>::JOINT VENTURE HAS BEEN ESTABLISHED BY UNIT SUN MORAL INTERNATIONAL AND STRIDES PHARMA GLOBAL PTE LIMITED.JOINT VENTURE IS OWNED AS TO 51% AND 49% BY SUN MORAL INTERNATIONAL AND STRIDES SINGAPORE SUBSIDIARY RESPECTIVELY.JOINT VENTURE WILL BE PRINCIPALLY ENGAGED IN BUSINESS OF REGISTRATION AND SALES FOR DRUGS.SJV WILL BE GIVEN EXCLUSIVE RIGHTS TO REGISTER, COMMERCIALIZE AND DISTRIBUTE FOUR PRODUCTS OF STRIDES IN CHINA.  Full Article

Strides Pharma Science Gets Warning Letter From USFDA Relating To Puducherry Facility
Tuesday, 2 Jul 2019 

July 2 (Reuters) - Strides Pharma Science Ltd ::RECEIVED WARNING LETTER FROM USFDA RELATING TO PUDUCHERRY FACILITY.PUDUCHERRY SITE CURRENTLY PRODUCES 6 ANDAS WHICH WILL NOT GET IMPACTED BY THE WARNING LETTER.10 ANDAS PENDING APPROVAL FROM PUDUCHERRY SITE WILL GET DEFERRED TILL SITE IS RECLASSIFIED.COMPANY RETAINS ITS GROWTH GUIDANCE FOR THE U.S. MARKET.  Full Article

India's Strides Pharma Science March Qtr Consol Net Profit Falls
Friday, 10 May 2019 

May 10 (Reuters) - Strides Pharma Science Ltd ::MARCH QUARTER CONSOL NET PROFIT 475.1 MILLION RUPEES VERSUS PROFIT OF 5.69 BILLION RUPEES LAST YEAR.MARCH QUARTER CONSOL REVENUE FROM OPERATIONS 8.40 BILLION RUPEES VERSUS 6.70 BILLION RUPEES LAST YEAR.  Full Article

Vivimed Labs Says Report On Vivimed Life Sciences' Drug Recall Has No Effect Co's Business
Wednesday, 8 May 2019 

May 8 (Reuters) - Vivimed Labs Ltd ::CLARIFIES ON REPORT VIVIMED LIFE SCIENCES PVT LTD RECALLS HYPERTENSIVE DRUG FROM U.S. MARKET DUE TO IMPURITIES.AFTER SALE OF STAKE IN 50:50 JV WITH STRIDES, CO SOLD BALANCE 50% STAKE IN VIVIMED LIFE SCIENCES TO STRIDES PHARMA SCIENCE.NEWS REPORT HAS NO EFFECT ON BUSINESS OF VIVIMED LABS.  Full Article

Strides Pharma Science Says USFDA Classifies Puducherry Facility As OAI
Monday, 6 May 2019 

May 6 (Reuters) - Strides Pharma Science Ltd ::STRIDES PHARMA SCIENCE - GETS COMMUNICATION FROM USFDA CLASSIFYING PUDUCHERRY FACILITY AS OAI BASED ON INSPECTION CONDUCTED FROM JAN 28- 5TH FEBRUARY.STRIDES PHARMA SCIENCE LTD - CLASSIFICATION WILL NOT HAVE AN IMPACT ON CURRENT SUPPLIES AND REVENUES FROM FACILITY.STRIDES PHARMA SCIENCE - OF 34 ANDA’S PENDING APPROVAL, PUDUCHERRY HAS 10 ANDA’S WHERE CO EXPECTS DELAYS UNTIL FACILITY IS RECLASSIFIED.  Full Article

Strides Pharma Science Gets U.S FDA Approval For Its Greenfield Oral Dosage Facility In Singapore
Wednesday, 27 Mar 2019 

March 27 (Reuters) - Strides Pharma Science Ltd ::RECEIVES USFDA APPROVAL FOR ITS GREENFIELD ORAL DOSAGE FACILITY IN SINGAPORE.  Full Article

Strides Pharma Science Says Bajaj Finance Cuts Stake In Co By 3.49 Pct To 1.74 Pct
Thursday, 14 Mar 2019 

March 14 (Reuters) - Strides Pharma Science Ltd ::SAYS BAJAJ FINANCE CUTS STAKE IN CO BY 3.49 PERCENT TO 1.74 PERCENT.  Full Article

Strides Pharma Science Seeks Shareholders' Nod For Divestment Of Australian Business
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Strides Pharma Science Ltd ::SEEKS SHAREHOLDERS' NOD FOR DIVESTMENT OF AUSTRALIAN BUSINESS.SEEKS SHAREHOLDERS' NOD FOR APPROVAL FOR DEALS WITH SOLARA ACTIVE PHARMA SCIENCES FOR UP TO 5 BILLION RUPEES IN EACH FY.  Full Article

India's Strides Pharma halts U.S. sales of heartburn drug

India's Strides Pharma Science Ltd said on Friday it has halted sales of its heartburn drug Ranitidine in the U.S. market as it conducts tests to identify possible cancer-causing impurities in the tablets.